FDA outlines what PMTAs must include: youth protection, comparative risk are key

The US Food and Drug Administration (FDA) today released its draft guidelines for premarket tobacco product applications (PMTAs), spelling out in detail the information that e-cigarette makers will have to submit before next year’s deadline and many of the criteria on which they will be judged.

Crucially for the industry, they acknowledge a continuum of risk in tobacco products, while also placing much emphasis on youth protection.

The broad thrust of of the draft requirements – which now go into a two-month comment period – has not changed from that long-established by the FDA: PMTA applications must show that placing a product on the market would be “appropriate for the protection of the public health”.

But three features in particular stand out as significant.

...

Need help?

Contact a sales representative right now and don’t wait

Erik Galavis
+34 654 320 547
Email Erik

Restricted content. Do you want to read more?

Request report

Interested in buying?
Request more information

MORE INFO

Visit store

Check out our reports
available for purchase

View reports

Request a free sample of this report:

“ FDA outlines what PMTAs must include: youth protection, comparative risk are key ”

    This file is not available, please fill the form to request your sample page:






    Buy report request information:

    “ FDA outlines what PMTAs must include: youth protection, comparative risk are key ”






      The US Food and Drug Administration (FDA) today released its draft guidelines for premarket tobacco product applications (PMTAs), spelling out in detail the information that e-cigarette makers will have to submit before next year’s deadline and many of the criteria on which they will be judged.

      Crucially for the industry, they acknowledge a continuum of risk in tobacco products, while also placing much emphasis on youth protection.

      The broad thrust of of the draft requirements – which now go into a two-month comment period – has not changed from that long-established by the FDA: PMTA applications must show that placing a product on the market would be “appropriate for the protection of the public health”.

      But three features in particular stand out as significant.

      ...

      Benefits of subscription plans:

      • Stay informed of any legal and market change in the sector that impacts your organization
      • Maximise resources by getting market and legal data analysis daily in one place
      • Make smart decisions by understanding how the regulatory and market landscape evolves
      • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization

      Need help?

      Contact a sales representative right now and don’t wait

      Erik Galavis
      +34 654 320 547
      Email Erik